Rose McNulty

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.

Real-world study shows plaque psoriasis stays controlled after 2 ustekinumab biosimilar switches, with stable labs and no serious adverse events.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

A CDC study found people vaccinated within the past six months were nearly half as likely to transmit SARS-CoV-2 to those they live with.

Seven-year CROWN trial data show lorlatinib's median PFS still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.

Lead ARACOG trial investigator Alicia Morgans, MD, discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.